beta-alanine has been researched along with Myocardial Infarction in 32 studies
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with warfarin, dabigatran is associated with less intracranial hemorrhage, but an increased risk of myocardial infarction." | 9.17 | Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? ( Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E, 2013) |
| "8) after an ST-elevation (60%) or non-ST-elevation (40%) myocardial infarction and randomized to twice daily treatment with dabigatran 50 mg (n = 369), 75 mg (n = 368), 110 mg (n = 406), 150 mg (n = 347), or placebo (n = 371)." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 8.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| "Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 8.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
| "For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 8.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
| "A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation." | 8.88 | Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012) |
| "What is the central question of the study? Does β-alanine with l-histidine supplementation associated with endurance and strength training improve echocardiographic parameters, functional capacity, and maximum strength in rats with chronic heart failure? What is the main finding and its importance? β-Alanine with l-histidine supplementation associated with endurance and strength training increased functional capacity and maximum strength through increasing exercise capacity peripherally but did not affect echocardiographic parameters in rats with chronic heart failure." | 7.96 | β-Alanine and l-histidine supplementation associated with combined training increased functional capacity and maximum strength in heart failure rats. ( Capalonga, L; da Silva, LR; Dal Lago, P; Stefani, GP, 2020) |
| "Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 7.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| " We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery." | 7.80 | Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014) |
| " New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 7.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
| "Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 7.79 | Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 7.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| "Compared with warfarin, dabigatran is associated with less intracranial hemorrhage, but an increased risk of myocardial infarction." | 5.17 | Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? ( Connolly, SJ; Coppens, M; Dale, B; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Paikin, JS; Weitz, JI; Whitlock, RP; Young, E, 2013) |
| "8) after an ST-elevation (60%) or non-ST-elevation (40%) myocardial infarction and randomized to twice daily treatment with dabigatran 50 mg (n = 369), 75 mg (n = 368), 110 mg (n = 406), 150 mg (n = 347), or placebo (n = 371)." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "Dabigatran is a direct, competitive inhibitor of thrombin recently approved for the prophylaxis of stroke and systemic embolism in patients with nonvalvular atrial fibrillation." | 4.90 | Increased risk of myocardial infarction with dabigatran: fact or fiction? ( Basile, E; Di Biase, L; Giglio, AF; Natale, A; Santangeli, P; Trotta, F, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "Dabigatran has been associated with greater risk of myocardial infarction (MI) than warfarin." | 4.89 | Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. ( Artang, R; Nielsen, JD; Rome, E; Vidaillet, HJ, 2013) |
| "Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and secondary stroke prevention and prevention of systemic embolism in patients with atrial fibrillation." | 4.88 | Preventing cardioembolic stroke in atrial fibrillation with dabigatran. ( Diener, HC; Eikelboom, JW; Hohnloser, SH; Weimar, C, 2012) |
| "The original RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) trial suggested a small increased risk of myocardial infarction (MI) with the use of dabigatran etexilate vs warfarin in patients with atrial fibrillation." | 4.88 | Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. ( Hernandez, AV; Uchino, K, 2012) |
| "For patients with atrial fibrillation and a high risk of thrombosis, the standard prophylaxis is warfarin, an anticoagulant, at a dose adjusted to the INR." | 4.88 | Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. ( , 2012) |
| "A network meta-analysis of the three new oral anticoagulants was performed from the three trials comparing dabigatran, rivaroxaban and apixaban with warfarin in patients with atrial fibrillation." | 4.88 | Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. ( Diener, HC; Harenberg, J; Lip, GY; Marder, VJ; Marx, S; Wehling, M; Weiss, C, 2012) |
| "What is the central question of the study? Does β-alanine with l-histidine supplementation associated with endurance and strength training improve echocardiographic parameters, functional capacity, and maximum strength in rats with chronic heart failure? What is the main finding and its importance? β-Alanine with l-histidine supplementation associated with endurance and strength training increased functional capacity and maximum strength through increasing exercise capacity peripherally but did not affect echocardiographic parameters in rats with chronic heart failure." | 3.96 | β-Alanine and l-histidine supplementation associated with combined training increased functional capacity and maximum strength in heart failure rats. ( Capalonga, L; da Silva, LR; Dal Lago, P; Stefani, GP, 2020) |
| "Large Phase 3 clinical trials for stroke prevention in atrial fibrillation (AF) have compared non-vitamin K antagonist oral anticoagulants (NOACs) against warfarin, with the edoxaban trial only recently reported." | 3.80 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. ( Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F, 2014) |
| "Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF)." | 3.80 | Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. ( Barón, AE; Bradley, SM; Carey, EP; Cunningham, F; Grunwald, GK; Ho, PM; Jackevicius, CA; Maddox, TM; Marzec, LN; Pilote, L; Rumsfeld, JS; Schneider, PM; Shore, S; Turakhia, MP; Varosy, PD, 2014) |
| " We present a case in which a patient abruptly stopped taking dabigatran due to a small bowel obstruction and shortly thereafter suffered a myocardial infarction complicated by left ventricular thrombosis with fatal embolisation to the superior mesenteric artery." | 3.80 | Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran. ( Marciniak, ET; McCurdy, MT; Reed, RM; Weiler, B, 2014) |
| " New oral anticoagulants (apixaban, rivaroxaban and dabigatran) are recommended for antithrombotic therapy in patients with non-valvular atrial fibrillation (NVAF) with moderate and high risk of stroke." | 3.80 | [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation]. ( Rudakova, AV; Tatarskiĭ, BA, 2014) |
| "Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF)." | 3.79 | Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. ( Bergh, M; Marais, CA; Miller-Jansön, H; Salie, F; Stander, MP, 2013) |
| "To estimate the quality-adjusted survival, costs, and cost-effectiveness of dabigatran compared with adjusted-dose warfarin for preventing ischemic stroke in patients 65 years or older with nonvalvular AF." | 3.77 | Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. ( Freeman, JV; Garber, AM; Go, AS; Hutton, DW; Owens, DK; Turakhia, MP; Wang, PJ; Zhu, RP, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 30 (93.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Stefani, GP | 1 |
| Capalonga, L | 1 |
| da Silva, LR | 1 |
| Dal Lago, P | 1 |
| Bergh, M | 1 |
| Marais, CA | 1 |
| Miller-Jansön, H | 1 |
| Salie, F | 1 |
| Stander, MP | 1 |
| Attia, JR | 1 |
| Pearce, R | 1 |
| Eikelboom, JW | 4 |
| Hankey, GJ | 1 |
| Shavadia, J | 1 |
| Welsh, RC | 1 |
| Artang, R | 2 |
| Rome, E | 1 |
| Nielsen, JD | 1 |
| Vidaillet, HJ | 1 |
| Messori, A | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Giglio, AF | 1 |
| Basile, E | 1 |
| Santangeli, P | 1 |
| Di Biase, L | 1 |
| Trotta, F | 1 |
| Natale, A | 1 |
| Molinier, A | 1 |
| Acket, B | 1 |
| Bourrel, R | 1 |
| Lavezzi, O | 1 |
| Montastruc, JL | 1 |
| Bagheri, H | 1 |
| Skjøth, F | 1 |
| Larsen, TB | 1 |
| Rasmussen, LH | 1 |
| Lip, GY | 2 |
| Shore, S | 1 |
| Carey, EP | 1 |
| Turakhia, MP | 2 |
| Jackevicius, CA | 1 |
| Cunningham, F | 1 |
| Pilote, L | 1 |
| Bradley, SM | 1 |
| Maddox, TM | 1 |
| Grunwald, GK | 1 |
| Barón, AE | 1 |
| Rumsfeld, JS | 1 |
| Varosy, PD | 1 |
| Schneider, PM | 1 |
| Marzec, LN | 1 |
| Ho, PM | 1 |
| Weiler, B | 1 |
| Marciniak, ET | 1 |
| Reed, RM | 1 |
| McCurdy, MT | 1 |
| Rudakova, AV | 1 |
| Tatarskiĭ, BA | 1 |
| Olesen, JB | 1 |
| Sørensen, R | 1 |
| Hansen, ML | 1 |
| Lamberts, M | 1 |
| Weeke, P | 1 |
| Mikkelsen, AP | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Fosbøl, EL | 1 |
| Pontillo, D | 1 |
| Patruno, N | 1 |
| Bultas, J | 1 |
| Christersson, C | 1 |
| Johnell, M | 1 |
| Siegbahn, A | 2 |
| Freeman, JV | 1 |
| Zhu, RP | 1 |
| Owens, DK | 1 |
| Garber, AM | 1 |
| Hutton, DW | 1 |
| Go, AS | 1 |
| Wang, PJ | 1 |
| Oldgren, J | 1 |
| Budaj, A | 1 |
| Granger, CB | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Tijssen, JG | 1 |
| Van de Werf, F | 1 |
| Wallentin, L | 1 |
| Moser, M | 1 |
| Bode, C | 1 |
| Weimar, C | 1 |
| Hohnloser, SH | 1 |
| Diener, HC | 2 |
| Redberg, RF | 1 |
| Jacobs, JM | 1 |
| Stessman, J | 1 |
| Uchino, K | 1 |
| Hernandez, AV | 1 |
| Mullard, A | 1 |
| Weitz, JI | 2 |
| Correia, LC | 1 |
| Lopes, AA | 1 |
| Harenberg, J | 1 |
| Marx, S | 1 |
| Marder, VJ | 1 |
| Wehling, M | 1 |
| Weiss, C | 1 |
| Dale, B | 1 |
| Young, E | 1 |
| Paikin, JS | 1 |
| Coppens, M | 1 |
| Whitlock, RP | 1 |
| Connolly, SJ | 1 |
| Ginsberg, JS | 1 |
| Hirsh, J | 1 |
| Allo, SN | 1 |
| Bagby, L | 1 |
| Schaffer, SW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Intervention to Improve Adherence to Dabigatran for Patients With Atrial Fibillation[NCT01578044] | 12 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)[NCT03515083] | 100 participants (Actual) | Interventional | 2017-07-17 | Completed | |||
| Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation[NCT04357288] | 1,200 participants (Anticipated) | Interventional | 2020-12-16 | Active, not recruiting | |||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study[NCT02376777] | 4,162 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The investigators will calculate the # of gap days between refills for dabigatran/rivaroxaban/apixaban for each3 and 6 months of the pilot intervention. This will be based on pharmacy refill data and calculated using the date dabigatran/rivaroxaban/apixaban was dispensed and the # of days supplied for that prescription. We will add the # of gap days for each 3 and 6 months of the pilot for each patient, and compare the total # of gaps days between intervention and usual care patients. The gap days between refills is a validated measure of adherence and identifies patients with sub-optimal adherence.A negative gap day value indicates that participants received the refill prior to completion of the previous prescription. (NCT01578044)
Timeframe: 3 and 6 months
| Intervention | days (Number) | |
|---|---|---|
| # of Patient gap days for 3-months of intervention | # of Patient gap days for 6-months of intervention | |
| Intervention Group | 43 | 41 |
| Usual Care Group | 51 | -5 |
7 reviews available for beta-alanine and Myocardial Infarction
| Article | Year |
|---|---|
Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors.
Topics: Amidines; Anticoagulants; Antithrombins; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamin | 2013 |
Increased risk of myocardial infarction with dabigatran: fact or fiction?
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatra | 2014 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Preventing cardioembolic stroke in atrial fibrillation with dabigatran.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as | 2012 |
Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Incidence; | 2012 |
Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; I | 2012 |
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cereb | 2012 |
2 trials available for beta-alanine and Myocardial Infarction
| Article | Year |
|---|---|
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Intracrania | 2013 |
23 other studies available for beta-alanine and Myocardial Infarction
| Article | Year |
|---|---|
β-Alanine and l-histidine supplementation associated with combined training increased functional capacity and maximum strength in heart failure rats.
Topics: Animals; beta-Alanine; Carnosine; Dietary Supplements; Echocardiography; Heart Failure; Histidine; M | 2020 |
Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Al | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardio | 2013 |
Is there really misuse and abuse of dabigatran?
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Myocard | 2013 |
Acute management of ST-elevation myocardial infarction patients taking dabigatran.
Topics: Aged; Antithrombins; Benzimidazoles; beta-Alanine; Coronary Artery Disease; Dabigatran; Drug-Eluting | 2013 |
Reply: To PMID 24075284.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Humans; Myocardial Infarction | 2014 |
Risk of myocardial infarction with oral direct thrombin inhibitors: trial sequential analysis based on two published data sets.
Topics: Antithrombins; Benzimidazoles; beta-Alanine; Humans; Myocardial Infarction | 2014 |
[Extrapolation of physiopathological data to clinical practice: Example of dabigatran in off-label use].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Contraindications; Dabigatr | 2014 |
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clini | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration.
Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cohort St | 2014 |
Myocardial infarction complicated by left ventricular thrombus and fatal thromboembolism following abrupt cessation of dabigatran.
Topics: Aged, 80 and over; Angiography; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Fatal Outco | 2014 |
[Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagu | 2014 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; be | 2015 |
Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Humans; M | 2015 |
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
Topics: Antithrombins; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Blood Platelets; Cell-Derived | 2010 |
Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cost-Ben | 2011 |
Redemption by RE-DEEM?
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Fibrinolytic Agents; Huma | 2011 |
Important data after drug approval: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial | 2012 |
Dabigatran: do we have sufficient data?: comment on "Dabigatran association with higher risk of acute coronary events".
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Myocardial | 2012 |
Anticoagulant loses its lustre.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Myocardial Infarction; Stroke | 2012 |
Anticoagulation therapy. Dabigatran and risk of myocardial infarction.
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction; | 2012 |
Dabigatran and myocardial infarction: meta-illusion?
Topics: Acute Coronary Syndrome; Benzimidazoles; beta-Alanine; Female; Humans; Male; Myocardial Infarction; | 2012 |
Taurine depletion, a novel mechanism for cardioprotection from regional ischemia.
Topics: Animals; beta-Alanine; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Ischemia; Myocar | 1997 |